12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Company News  |  Other News

BioCryst cardiovascular, infectious news

BioCryst said it will reduce headcount by 38 (50%) to 37 and focus its resources on BCX4161 for hereditary angioedema (HAE) and preclinical antiviral programs BCX4430 and BCX5191. The move follows major pipeline setbacks and the mutual termination last month of a proposed merger with Presidio Pharmaceuticals Inc. (San Francisco, Calif.). BioCryst said...

Read the full 272 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >